Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., . . . Moreau, P. (2023). Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial. Journal of clinical oncology, 41(8), . https://doi.org/10.1200/JCO.22.00940
Chicago-Zitierstil (17. Ausg.)Dimopoulos, Meletios A., et al. "Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-label, Phase III Trial." Journal of Clinical Oncology 41, no. 8 (2023). https://doi.org/10.1200/JCO.22.00940.
MLA-Zitierstil (9. Ausg.)Dimopoulos, Meletios A., et al. "Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-label, Phase III Trial." Journal of Clinical Oncology, vol. 41, no. 8, 2023, https://doi.org/10.1200/JCO.22.00940.